What the best looks like

Proprietary HT-SPR™ technology

  • 100x the data
  • 10% of the time to answer
  • 1% of the sample requirements of other platforms

Contact Us


  • Market leader in high-throughput antibody characterization
  • Detailed antibody kinetics and epitope binning at the earliest stages of drug discovery
  • Characterization directly from crude material

Learn More


  • All the benefits of LSA plus enhanced data quality for the most demanding applications
  • Rapid kinetics and weak binders such as FcγRs and cytokine panels
  • Small analyte formats such as peptides, PROTAC®s, and protein inhibitors

Learn More

There’s no faster way to discover a therapeutic drug or vaccine.

The fastest, most sensitive, and flexible biosensor platform… ever.

Eli Lilly developed bamlanivimab, the world’s First COVID-19 therapeutic, on the Carterra LSA platform in a 90-day sprint.

Learn More

This is what high throughput kinetics looks like.

You can’t generate this much data any other way.  And if you’re wondering:

  • Screening and characterization in the same step — 384 full kinetic profiles in a day
  • 50x faster — Data quality is the same as your low throughput gold standard instrument
  • 1% of the sample you’ve been pouring into your current biosensor

Learn More

This is what a high-res epitope binning looks like.

If you’re not binning or just binning 10s of antibodies at a time, you’re not finding out much about your epitope.

  • Bin up to 384 × 384 antibodies (that’s about 150,000 sensorgrams if you’re wondering)
  • Discover the Mechanism of Action quickly and reduce failures in development and the clinic
  • Obtain Intellectual Property rights and lock down features that differentiate your antibody from your competitors

Learn More

Want to Learn More?

Speak to a Carterra Scientist

News & Events

2024 Carterra Symposia



2024 Carterra Symposia

Read More


Check out the Science Webinar: Advances in HT-SPR, scBCR-seq and RNA-seq

View the Webinar


Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern